Pictet Asset Management Holding SA Sells 277,329 Shares of CVS Health Corporation $CVS

Pictet Asset Management Holding SA decreased its position in CVS Health Corporation (NYSE:CVS) by 33.4% during the 1st quarter, Holdings Channel.com reports. The fund owned 553,318 shares of the pharmacy operator’s stock after selling 277,329 shares during the quarter. Pictet Asset Management Holding SA’s holdings in CVS Health were worth $39,731,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CVS. TOWER TRUST & INVESTMENT Co lifted its position in CVS Health by 0.8% during the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock valued at $1,247,000 after purchasing an additional 132 shares during the period. CYBER HORNET ETFs LLC grew its position in shares of CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after buying an additional 134 shares during the period. LS Investment Advisors LLC raised its stake in shares of CVS Health by 3.9% during the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after buying an additional 135 shares during the last quarter. Moss Adams Wealth Advisors LLC lifted its holdings in CVS Health by 4.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock valued at $239,000 after buying an additional 135 shares during the period. Finally, Northwestern Mutual Investment Management Company LLC boosted its stake in CVS Health by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after acquiring an additional 136 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

CVS has been the subject of a number of analyst reports. Argus lifted their target price on shares of CVS Health from $90.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Mizuho raised their price target on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Piper Sandler reaffirmed an “overweight” rating and set a $113.00 price objective on shares of CVS Health in a research note on Monday, June 1st. Wells Fargo & Company upped their price objective on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, JPMorgan Chase & Co. raised their target price on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Twenty-one analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $101.28.

Insider Transactions at CVS Health

In related news, Director Larry Robbins sold 370,462 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is currently owned by insiders.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health has been featured in articles highlighting its strong fundamentals and recent move to a fresh 52-week high, suggesting investors still see room for upside if earnings and guidance remain solid.
• Positive Sentiment: The company’s marketing and brand-building efforts tied to America250 are reinforcing CVS Health’s public-facing profile, which may help support broader consumer engagement and brand strength.
• Neutral Sentiment: CVS Health also published health-screening content aimed at encouraging preventive care, which is positive for brand awareness but unlikely to move the stock on its own.
• Neutral Sentiment: A Wall Street Zen downgrade to Hold adds a cautious note, but it does not appear to be a major driver compared with the stock’s recent strength.
• Negative Sentiment: Florida has opened a probe into CVS Health over alleged pharmacy steering, raising the risk of regulatory scrutiny, possible legal costs, and renewed investor concern about pharmacy benefit manager practices. Florida probes CVS Health over alleged pharmacy steering
• Negative Sentiment: Industry coverage noting that UnitedHealth, Humana, and CVS have denied some post-hospital care at high rates could keep attention on utilization management and reimbursement practices, which may pressure sentiment around managed-care and pharmacy operations.

CVS Health Trading Up 0.0%

Shares of NYSE CVS opened at $103.59 on Wednesday. CVS Health Corporation has a twelve month low of $58.50 and a twelve month high of $106.15. The stock has a market cap of $132.17 billion, a price-to-earnings ratio of 45.63, a P/E/G ratio of 1.01 and a beta of 0.62. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. The company’s fifty day moving average is $92.88 and its 200-day moving average is $82.79.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Equities research analysts predict that CVS Health Corporation will post 7.44 EPS for the current year.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.